期刊文献+

【特刊综述】睾酮和雌二醇检测方法面临的挑战和取得的进展 被引量:3

Challenges and improvements in testosterone and estradiol testing
下载PDF
导出
摘要 Assays that measure steroid hormones in patient care, public health, and research need to be both accurate and precise, as these criteria help to ensure comparability across all clinical and research applications. This review addresses major issues relevant to assay variability and describes recent activities by the US Centers for Disease Control and Prevention (CDC) to improve assay performance. Currently, high degrees of accuracy and precision are not always met for testosterone and estradiol measurements; although technologies for steroid hormone measurement have advanced significantly, measurement variability within and across laboratories has not improved accordingly. Differences in calibration and specificity are discussed as sources of variability in measurement accuracy. Ultimately, a combination of factors appears to cause inaccuracy of steroid hormone measurements, with nonuniform assay calibration and lack of specificity being two major contributors to assay variability. Within-assay variability for current assays is generally high, especially at low analyte concentrations. The CDC Hormone Standardization (HoSt) Program is improving clinical assays, as evidenced by a 50% decline in mean absolute bias between mass spectrometry assays and the CDC reference method from 2007 to 2011. This program provides the measurement traceability to CDC reference methods and helps to minimize factors affecting measurement variability. Assays that measure steroid hormones in patient care, public health, and research need to be both accurate and precise, as these criteria help to ensure comparability across all clinical and research applications. This review addresses major issues relevant to assay variability and describes recent activities by the US Centers for Disease Control and Prevention (CDC) to improve assay performance. Currently, high degrees of accuracy and precision are not always met for testosterone and estradiol measurements; although technologies for steroid hormone measurement have advanced significantly, measurement variability within and across laboratories has not improved accordingly. Differences in calibration and specificity are discussed as sources of variability in measurement accuracy. Ultimately, a combination of factors appears to cause inaccuracy of steroid hormone measurements, with nonuniform assay calibration and lack of specificity being two major contributors to assay variability. Within-assay variability for current assays is generally high, especially at low analyte concentrations. The CDC Hormone Standardization (HoSt) Program is improving clinical assays, as evidenced by a 50% decline in mean absolute bias between mass spectrometry assays and the CDC reference method from 2007 to 2011. This program provides the measurement traceability to CDC reference methods and helps to minimize factors affecting measurement variability.
出处 《Asian Journal of Andrology》 SCIE CAS CSCD 2014年第2期178-184,I0006,I0007,共9页 亚洲男性学杂志(英文版)
关键词 CDC hormone standardization CDC HoSt ESTRADIOL steroid hormone testing TESTOSTERONE CDC hormone standardization CDC HoSt estradiol steroid hormone testing testosterone
  • 相关文献

参考文献69

  • 1Meier C, Nguyen rv, Handelsman D J, Schindler C, Kushnir MM, et al. Endogenous sex hormones and incident fracture risk in older men: the dubbo osteoporosis epidemiolosy study. Arch Intern Med 2008, 168: 47-54.
  • 2Rodriguez A, Muller DC, Metter E J, Maggio M, Harman SM, etaL Aging, androgens, and the metabolic syndrome in a longitudinal study of aging. J Clin Endocrinol Metab 2007, 92: 3568-72.
  • 3Bhasin S, Jasjua GK, Pencina M, D'Agostino R Sr, Coviello AD, et al. Sex hormone-binding globulin, but not testosterone, is associated prospectively and independently with incident metabolic syndrome in men: the framingham heart study. Diabetes Care 2011, 34: 2464-70.
  • 4Feldman HA, Longcope C, Derby CA, Johannes CB, Araujo AB, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab 2002, 87: 589-98.
  • 5Selvin E, Feinleib M, Zhang L, Rohrmann S, Rifai N, etal. Androgens and diabetes in men: results from the Third National Health and Nutrition Examination Survey {NHANES Ⅲ). Diabetes Care 2007, 30: 234-8.
  • 6Wurtz AM, Tjonneland A, Christensen J, Dragsted LO, Aarestrup J, et al. Serum estrogen and SHBG levels and breast cancer incidence among users and never users of hormone replacement therapy. Cancer Causes Control 2012, 23:1711-20.
  • 7Lin JH, Zhang SM, Rexrode KM, Manson JE, Chan AT, et al. Association between sex hormones and colorectal cancer risk in men and women. Clin Gastroenterol Hepato12013, 11: 419-24.
  • 8Zhang X, Tworoger SS, Eliassen AH, Hankinson SE. Postmenopausal plasma sex hormone levels and breast cancer risk over 20 years of follow-up. Breast Cancer Res Treat 2013, 137: 883-92.
  • 9Hougaku H, Fleg JL, Najjar SS, Lakatta EG, Harman SM, et al. RelatFonship1 between androgenic hormones and arterial stiffness, based on longitudinal hormone measurements. Am J Physiol Endocrinol Metab 2006, 290: E234-42.
  • 10Moskovic D J, Araujo AB, Lipshuttz LI, Khera M. The 20-year public health impact and direct cost of testosterone deficiency in U.S. men. J Sex Med 2013, 10: 562-9.

同被引文献14

引证文献3

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部